ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1130

Predictors of Mortality in COVID-19 Patients Diagnosed with AKI: A Case-Control Study

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Aroca Martinez, Gustavo, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Russi Pulgar, Daniela, Universidad del Norte Division Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Velez, Maria De Los Ángeles, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Musso, Carlos Guido, Universidad Simon Bolivar Facultad de Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Dominguez-Vargas, Alex, Universidad del Norte Division Ciencias de la Salud, Barranquilla, Atlántico, Colombia
  • Navarro-Lechuga, Edgar, Universidad del Norte Division Ciencias de la Salud, Barranquilla, Atlántico, Colombia
Background

COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a multi-systemic infection with various manifestations, including acute kidney injury (AKI). This study aimed to identify factors associated with mortality in COVID-19 patients diagnosed with AKI during hospitalization at Clínica de la Costa in Barranquilla, Colombia from 2020 to 2022.

Methods

A case-control study. COVID-19 patients with acute kidney injury (AKI) were enrolled. Cases included fatal outcomes, while controls survived. AKI was defined using The Kidney Disease: Improving Global Outcomes criteria. A range of independent variables, including sociodemographic characteristics, comorbidities, initial laboratory parameters, and clinical features, were examined. Inferential analysis was performed using Chi-square, t-test, and Mann-Whitney U tests (p < 0.05). Associations were further evaluated using logistic regression, and odds ratios (ORs) with 95% confidence intervals were calculated.

Results

The study sample included 159 cases (deceased) and 74 controls (survivors). The average age in the deceased group was 66 ± 14 years, significantly higher than the average age of 59 ± 17 years in the survivor group (p-value = 0.005). No statistically significant differences were observed in terms of gender (p-value = 0.278) and municipality of residence (p-value = 0.078) between the study groups. The final adjusted model revealed several significant risk factors for mortality, including admission to the intensive care unit (OR = 4.8; 95% CI 1.5-15.6), invasive mechanical ventilation (OR = 51.1; 95% CI 10.9-240.7), renal replacement therapy (OR = 11.7; 95% CI 1.1-123.0), and Acute Kidney Injury Network (AKIN) II classification (OR = 8.8; 95% CI 2.5-30.5).

Conclusion

It is crucial for healthcare providers to maintain heightened surveillance in Covid-19 patients with AKI who require ICU admission, IMV, and RRT, as these factors are associated with higher mortality rates.

Funding

  • Clinical Revenue Support